Revenues, Significant Customers and Concentrations of Risk (Tables)

12 Months Ended

Dec. 31, 2019

Revenue From Contract With Customer [Abstract]

Summary of Revenues Disaggregated by Major Types and Sources and Customer Geographic Location

The following table presents the Company’s revenue on a disaggregated basis by major types and sources:

	For the Years Ended December 31,
	2019		2018		2017
Proprietary product sales	$	39,215	$	17,532	$	17,946
Partnered product sales		52,888		30,338		23,749
Total product revenue		92,103		47,870		41,695
Licensing and development revenue		7,529		6,753		11,171
Royalties		24,232		8,931		1,649
Total revenue	$	123,864	$	63,554	$	54,515

Revenues disaggregated by customer geographic location are summarized as follows:

	For the Years Ended December 31,
	2019		2018		2017
United States of America	$	120,231	$	57,033	$	48,924
Europe		3,463		6,157		5,061
Other		170		364		530
	$	123,864	$	63,554	$	54,515

Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue

Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows: 

	For the Years Ended December 31,
	2019	2018	2017
Teva	41%	31%	38%
AMAG	20%	29%	16%
AmerisourceBergen(1)	10%	11%	11%
McKesson (1)	<10%	12%	16%
Ferring	<10%	11%	10%

⁽¹⁾ Revenue from sales to distributors, net of estimated sales returns and allowances based on shipments.